Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Confo PTHR1 agonist
- Development stage
- Preclinical
- Lead developer
- Confo Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Confo PTHR1 agonist is a small molecule drug candidate being developed by Confo Therapeutics for the treatment of hypoparathyroidism. The program utilizes Confo's proprietary ConfoBody technology, which employs camelid-derived single-domain antibodies (nanobodies) to stabilize G-protein coupled receptors (GPCRs) in their active state, enabling the discovery of high-affinity small molecule agonists. By targeting the Parathyroid Hormone Receptor 1 (PTHR1), the drug aims to mimic the action of endogenous parathyroid hormone (PTH) to restore calcium and phosphate homeostasis. This approach is intended to provide a more convenient, potentially oral, alternative to current peptide-based hormone replacement therapies that require frequent injections.
- Other names
- PTHR1 small molecule programPTHR-1 small molecule programPTHR 1 small molecule programConfo Therapeutics PTHR1 programHypoparathyroidism ProgramConfo Therapeutics-PTHR1-small molecule-Hypoparathyroidism
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on Confo PTHR1 agonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Confo PTHR1 agonist.